Barclays analyst Andrew Mok lowered the firm’s price target on Humana (HUM) to $268 from $273 and keeps an Equal Weight rating on the shares as part of an investor day preview. The firm expects the company to outline embedded earnings and the path to 3% Medicare Advantage margins, but does not anticipate any formal earnings targets or 2026 guidance.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Trump Trade: Tesla bouncing back after $152B in market cap loss amid Musk spat
- Senate Republicans consider Medicare spending cuts, Bloomberg says
- UnitedHealth, Humana, CVS fall after Bloomberg report on possible Medicate cuts
- Humana to support moves to curb Medicare billing practices, WSJ says
- Trump Trade: Trump says Fed ‘must now’ lower rates after jobs report
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue